Castle Biosciences (CSTL) stock

Cancer tests , market cap $1.0B

Cancer tests

Worth $1.0B

$34.42

+0.12%

As of Tuesday's close · Live for Pro members at the open

Why CSTL fell 11% since Oct 29

Down 11% from Oct 29 to Nov 10.

Its Nov 5 results: adjusted net loss per share, basic and diluted widened to $0.13, from $0.02 a year before. It fell 5% on Nov 6.

Sources: Price history, Nov 10, 2026; Company release, Nov 5, 2026

Tell me next time CSTL moves

Free account, no card. An optional alert when CSTL moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →2 more reasons why CSTL fell 11% since Oct 29, from its filings, with the other side, the timeline, and its peers, for Pro members.

Quality Score

Average

In its industry

#9of 18

Diagnostics

Checks firing

5of 14

Transition

From 52-week high

-22.3%

under its best in a year

CSTL's Quality Score rose 2 points on Tue, Nov 10, to 8. Its high and its low were both higher than the day before (2 chart checks started).

See CSTL's 14 chart checksSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on CSTL

Key facts on CSTL
Outperforming	Up 85% in 6 months vs the S&P's +2%
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind CSTL's 8, free with an account →1 more reason behind CSTL's 8, for Pro members.

CSTL in the news

Wed Oct 28Castle from Taylor Swift's 'Blank Space' Finds a Buyer for $72 Million at Auction AOL and 4 more CSTL closed +6.3% that day.

What's next

Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

CSTL catalysts

Coming up

After its last 4 reports it closed -7.5% on average, higher 1 of 4 times.

12 past catalysts since 2021, with sizes and sources, for Pro members.

Why CSTL scores 8

Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. CSTL scores 8 today, against a median of 4 over its last 20 recorded sessions.

+5Chart checks 5 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.

No effect today: Size, Growth, Dilution, Volatility, Cash flow, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on CSTL and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:01 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How CSTL ranks in Diagnostics

CSTL is #9 of 18 by Quality Score.

How CSTL ranks in Diagnostics
Rank	Stock	Checks	Quality Score
1	CDNACareDx	4/14	16
2	BLLNBillionToOne	5/14	16
3	LHLabcorp	7/14	16
	CAICaris Life Sciences		Open for its score
	DGXQuest Diagnostics		Open for its score
	FRNMFreenome		Open for its score
9	CSTLCastle Biosciences	5/14	8

When does CSTL report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CSTL reported on Nov 5, 2026

The quarter

Sales of $102.9M, 24% more than a year ago; a loss of $0.13 a share, from $0.02.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Non-Dermatologicup 59%	$55M53%	$54.8M53%	$34.5M42%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total revenue	$385.00raised

Figures as filed (SEC filing, Nov 5)

1 more outlook line, for Pro members.

The numbers

Market value: $1B; today
Sales: $377M; up 9.8% on the year
Free cash flow: $4M; last 12 months

Sales grew 41% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 8.9% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CSTL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-22.3%+4.5%-4.9%

May 6Jul 30Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	+1.1%	-4.9%	not yet
Jul 30, 2026After close	After close	+7.3%	+4.5%	+13.7%
May 6, 2026After close	After close	-8.4%	-22.3%	-26.7%

CSTL closed higher after 1 of its last 4 reports.

All 4 reports, and CSTL's Quality Score going into each

CSTL sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $344M. It lost money in 2025 after a profit in 2024.

CSTL has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on CSTL, and all 14 on every stock.Get in free →

CSTL RSI today: 50.1, above its 50-day and 200-day averages

Not scored

RSI 50.1, MACD below signal, above both averages. Not scored.13 readings

The deep dive on CSTL

What it does and how it makes money3 findingsAn operating loss of $42.8M in fiscal 2025, on $344M of sales.Annual report, filed Feb 26, 2026
Where it stands4 findingsFor Pro members4 findings on where CSTL stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findingsA new heading in its "Risk Factors" this year: "Failure to timely obtain necessary marketing authorizations for our products that are intended for clinical or diagnostic uses may have a material adverse effect on our business, financial condition, results of operations, and prospects." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 26, 2026, against the one of Feb 27, 2025
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades CSTL, for Pro members

11 more findings on CSTL, each with its source, for Pro members.

CSTL insider trades

2 insiders sold $1.6M across 4 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellKristen M. Oelschlager$412KChief Operating Officerat $33.69 on Aug 24, filed Aug 26

SellKristen M. OelschlagerChief Operating Officer$412Kat $33.69 on Aug 24, filed Aug 26

All 4 insider filings on CSTL from the last six months, for Pro members.

All CSTL insider trades

CSTL's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Frank StokesChief Financial Officer · 5 trades
Derek J. MaetzoldPres. & Chief Exec. Officer · 42 trades
Tobin W. JuvenalChief Commercial Officer · 18 trades
Kristen M. OelschlagerChief Operating Officer · 10 trades
G. Bradley ColeDirector · 2 trades
Daniel BradburyDirector · no trades on file
Ellen GoldbergDirector · no trades on file
Kim CapleDirector · no trades on file

3 more officers and directors file at CSTL.

See insider trades by person

Which ETFs hold CSTL?

In ETFs: CSTL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Castle Biosciences

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

1,002 employeesFriendswood, TXcastlebiosciences.com

What Castle Biosciences says it competes with

“Today, our principal competition for DecisionDx-Melanoma is existing traditional clinical and pathology staging criteria.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on CSTL and every other stock.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move CSTL's score: 5 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 26Kristen M. Oelschlager sold CSTL$412K at $33.69, filed Aug 26

Alerts are optional.

See CSTL's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: CSTL's Quality Score is 8 (Average), #9 of 18 in Diagnostics. Insiders sold $1.6M in the last 6 months (Form 4).

What does CSTL's Quality Score say?

CSTL scores 8 today, which Breakaway calls Average. It is #9 of 18 in Services-⁠Medical Laboratories by Quality Score, with 5 of 14 chart checks firing. Down 11% from Oct 29 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CSTL's Quality Score?

CSTL scores 8 today, which Breakaway calls Average (6 to 10). That is #9 of 18 in Services-⁠Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CSTL's 8.

Are insiders buying CSTL?

2 insiders sold $1.6M across 4 filings in the last 6 months. No open-⁠market buys on record. The newest is Kristen M. Oelschlager, Chief Operating Officer, who sold $412K on Aug 24. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.